Lilly’s Donanemab Set For Broad Indication, No Tau PET Imaging Condition Following US FDA Panel Nod

Smooth sailing
It was smooth sailing for Lilly's donanemab at an FDA advisory committee meeting. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers